跳到正文
原文
The Lancet· Riccardo Papa, Susan Rhee, Patricia Delai, Keqin Zhang, Ignacio Briceño Balcázar, Kavitha Rethanavelu, Toshifumi Fujiwara, Kenichi Mishima, Jacek Tabarkiewicz, Thomas Funck-Brentano, Raphaella Stander, Javier Bachiller-Corral, Kathryn M Dahir, E Marelise W Eekhoff, Matti Hero, Evelyn Kuong, Naoto Uemura, Meijian Zhou, Dinko Gonzalez Trotter, Jing Gu, Robert J Sanchez, Donal Óg O’Donovan, Aris N Economides, Robert Pordy, Boaz Hirshberg, George D Yancopoulos, Richard Keen, OPTIMA Study Group·· 2026-09-29精选AI 评分78

garetosmab在FOP III期OPTIMA试验中显著减少新发异位骨病灶

[Articles] Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial

AI 导读

《柳叶刀》发表的随机、双盲、安慰剂对照III期OPTIMA试验显示,activin A阻断抗体garetosmab显著减少进行性骨化性纤维发育不良(FOP)患者新发异位骨病灶的数量。研究结论认为,该药有望成为有效且总体耐受良好的FOP疾病修饰疗法。

推荐理由

III期OPTIMA试验显示garetosmab减少FOP患者新发异位骨病灶,为这一罕见病提供疾病修饰疗法的证据。

来源:The Lancet · thelancet.com